Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: are we investing or gambling

April 14, 2021 7:34am

A little bit of both in this volatile market and see-sawing sector

Pre-open indications: 2 BUY, 4 SELLs and 1 Maintain SELL

Mentions: ALNY, SAGE, BSTG, VCEL, CRSP, EDIT, QURE, VCEL

My version of the morning’s “numbers” is written to be informative rather than just about changes to share pricing; it’s what happened or will materialize after the opening and what might happen in the session

My comments are important in trying to distinguish the temporary from real pricing progress.

Dow futures are DOWN -0.08% (-27 points), S&P futures are UP +0.06% (+3 points) and NASDAQ futures are UP +0.26% (+37 points)

U.S. stock futures were mixed in Wednesday’s pre-open,

European markets were slightly higher,

Asia Pacific markets were mixed.

Data Docket: Fed Chair Powell speaks virtually to the Economic Cub of Washington

Henry’omics:

Bank earnings begin today setting the tone of the session and days to come.

The cell and gene therapy sector traded negative on Monday bouncing higher on Tuesday while a March inflation report turned out not as bad as some traders feared, but the session was impacted by the halt to the rollout of Johnson & Johnson (JNJ) vaccine kept optimism in check.

Tuesday’s evening’s recap: “RegMed Investors’ (RMi) closing bell: the gain and thee pain with a spike, a flame -up and a shake-off after JNJ vaccine halted. Sustainability is in serious flux.” … https://www.regmedinvestors.com/articles/11864

The Nasdaq closed UP +146.10 points (+1.05%);
The IBB closed up +1.85% and XBI closed up +1.46%;
Sector volume was LOW with 3 of the 23-upside having higher than the 3-month average volume with the volume of 1 of 11 downside having higher than the 3-month average volume;
The CBOE Volatility Index (VVIX: INDEX) was down -0.26 points or – 1.54% at 16.65;
Tuesday’s percentage (%) of the 23-upside were +0.14% (FIXX) to +6.03% (RARE) while the 11-downside ranges from -0.08% (MDXG) to -5.13% (BSTG);

Q2/21 and April: 4 negative and 4 positive closes

Q1/21:

March: 10 positive, 12 negative and 1 neutral closes
February: 9 positive, 10 negative closes and 1 holiday
January: 10 positive, 9 negative closes and 1 holiday

Companies in my headlights – It’s your decision; I provide an idea and context:

Biostage (BSTG): Questions continue … Maintaining Sell

Biostage (BSTG) closed down again -$0.06 to $1.11 with 1,165 shares traded after Monday’s -$0.08 to $1.17 with 3,631 shares traded, Friday’s flat at $1.25 with 260 shares traded, Thursday with 6 shares traded and last Wednesday’s $1.25 with 967 shares traded.

Question#1: HOW many executives or management “team members” remain at the company? Is the website truthful and up-to-date regarding those WHO have left for other positions?

Question2: WHO is in charge of clinical and pre-clinical development?

Question#3: WHAT is behind the volatility and daily volume relationship and WHO is “propping” the share pricing (review the differences).

Question#4: BSTG must be glad to file the LATE Q4 and FY20 “numbers; are they sure they have included all the PAST accounts payable and accumulated liabilities?

MINORITY PUBLIC shareholders are waiting, watching and weighing responses to MAINTAIN their RIGHTS.

BUY on news:

Alnylam Pharmaceuticals (ALNY) closed up +$1.20 to $136.23 with a positive +$4.25 or +3.12% aftermarket indication on Monday’s news of reporting positive interim data from its ongoing P1 study of ALN-AGT. The company is evaluating ALN-AGT for the treatment of hypertension.

Sage Therapeutics (SAGE) closed down -$2.92 to $71.76 and has a positive +$1.56 or +2.17% aftermarket indication on news that SAGE and partner Biogen (BIIB) reported that the mid-stage study, KINETIC, on SAGE-324 for the treatment of people with essential tremor (ET) was successful. SAGE-324 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). KINETIC is a P2 study that evaluated the efficacy, safety and tolerability of SAGE-324 60 mg in 69 patients with ET, aged 18-80 years.

.

SELL into Strength:

Editas Medicine (EDIT) closed up +$2.15 to $41.66 after Monday’s $39.51, Friday’s $39.46, Thursday’s $40.76 and last Wednesday’s $40.40 with a negative -$0.41 or -0.98% aftermarket indication.

CRISPR Therapeutics (CRSP) closed up +$6.49 to $120.88 after Monday’s -$1.35 to $114.39, Friday’s -$4.64 to $115.74, Thursday’s $120.38 and last Wednesday’s $118.53 with a positive +$1.11 or +0.92% pre-market indication.

uniQure NV (QURE) closed up +$1.74 to $34.88 after Monday’s -$0.60 to $33.14, Friday’s $33.74, Thursday’s $35.48 and last Wednesday’s $34.52 with a negative -$0.18 or -0.52% aftermarket indication.

Maintaining SELL:

Vericel (VCEL) closed down -$1.58 to $56.60 after Monday’s +$0.41 to $58.18, Friday’s -$2.05 to $57.77, Thursday’s +$4.35 to $59.82 and last Wednesday’s $55.47 with a negative -$1.40 or -2.47% aftermarket indication; but an Icarus flight pattern.

The BOTTOM LINE: Volatility boosted by a see-sawing sentiment brought on by electronic trading versus investing.

Again, “Momentum is fragmented, volatility exceeds volume and we shouldn’t base our buying or selling positions in this climate of prospects that have lately gone unfulfilled!”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!”

Welcome to my world of defining the “grey’ in our universe!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.